Targeted activation of HNF4α/HGF1/FOXA2 reverses hepatic fibrosis via exosome-mediated delivery of CRISPR/dCas9-SAM system
Abstract
Aim: Hepatic fibrosis is one of the most common conditions worldwide, and yet no effective antifibrotic therapy is available. This study aimed to reverse hepatic fibrosis via exosome-mediated delivery of the CRISPR/dCas9-SAM system. Materials & methods: The authors constructed a modified-exosome delivery system targeting hepatic stellate cells (HSCs), and constructed the CRISPR/dCas9-SAM system inducing HSCs convert into hepatocyte-like cells in vitro and in vivo. Results: RBP4-modified exosomes could efficiently load and deliver the CRISPR/dCas9 system to HSCs. The in vitro CRISPR/dCas9 system induced the conversion from HSCs to hepatocyte-like cells via targeted activation of HNF4α/HGF1/FOXA2 genes. Importantly, in vivo targeted delivery of this system significantly attenuated CCl4-induced hepatic fibrosis. Conclusion: Targeted activation of HNF4α/HGF1/FOXA2 reverses hepatic fibrosis via exosome-mediated delivery of the CRISPR/dCas9-SAM system, which provides a feasible antifibrotic strategy.
Graphical abstract
References
- 1. Sirt6 alleviated liver fibrosis by deacetylating conserved lysine 54 on Smad2 in hepatic stellate cells. Hepatology 73(3), 1140–1157 (2021).
- 2. . Molecular and cellular mechanisms of liver fibrosis and its regression. Nat. Rev. Gastroenterol. Hepatol. 18(3), 151–166 (2021).
- 3. . Myofibroblast YAP/TAZ is dispensable for liver fibrosis in mice. J. Hepatol. 75(1), 238–241 (2021).
- 4. . Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues. Mol. Aspects Med. 65, 37–55 (2019).
- 5. Liver-specific deletion of mouse Tm6sf2 promotes steatosis, fibrosis, and hepatocellular cancer. Hepatology 74(3), 1203–1219 (2021).
- 6. . Liver cirrhosis. Lancet 398(10308), 1359–1376 (2021).
- 7. . Hepatic fibrosis 2022: unmet needs and a blueprint for the future. Hepatology 75(2), 473–488 (2022).
- 8. . Liver regeneration requires Yap1-TGFbeta-dependent epithelial-mesenchymal transition in hepatocytes. J. Hepatol. 69(2), 359–367 (2018).
- 9. . Liver regeneration: biological and pathological mechanisms and implications. Nat. Rev. Gastroenterol. Hepatol. 18(1), 40–55 (2021).
- 10. . Liver regeneration and inflammation: from fundamental science to clinical applications. Nat. Rev. Mol. Cell Biol. 22(9), 608–624 (2021).
- 11. Somatic mutations increase hepatic clonal fitness and regeneration in chronic liver disease. Cell 177(3), 608–621 e612 (2019).
- 12. Shear stress-induced cellular senescence blunts liver regeneration through Notch-sirtuin 1-P21/P16 axis. Hepatology 75(3), 584–599 (2022).
- 13. . Reply to: “Myofibroblast YAP/TAZ is dispensable for liver fibrosis in mice.” J. Hepatol. 75(1), 241–243 (2021).
- 14. . Mechanisms of hepatic stellate cell activation. Nat. Rev. Gastroenterol. Hepatol. 14(7), 397–411 (2017).
- 15. . The power of plasticity – metabolic regulation of hepatic stellate cells. Cell Metab. 33(2), 242–257 (2021).
- 16. FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretome. Nat. Cell Biol. 22(6), 728–739 (2020).
- 17. . Pathobiology of liver fibrosis: a translational success story. Gut 64(5), 830–841 (2015).
- 18. Single-cell transcriptomic analysis reveals a hepatic stellate cell-activation roadmap and myofibroblast origin during liver fibrosis in mice. Hepatology 74(5), 2774–2790 (2021).
- 19. . Determinants of fibrosis progression and regression in NASH. J. Hepatol. 68(2), 238–250 (2018).
- 20. Hexa histidine-tagged recombinant human cytoglobin deactivates hepatic stellate cells and inhibits liver fibrosis by scavenging reactive oxygen species. Hepatology 73(6), 2527–2545 (2021).
- 21. CDKN2a/p16 antagonizes hepatic stellate cell activation and liver fibrosis by modulating ROS levels. Front. Cell Dev. Biol. 8, 176 (2020).
- 22. Role of aldosterone in the activation of primary mice hepatic stellate cell and liver fibrosis via NLRP3 inflammasome. J. Gastroenterol. Hepatol. 35(6), 1069–1077 (2020).
- 23. Metabotropic glutamate receptor 5 in natural killer cells attenuates liver fibrosis by exerting cytotoxicity to activated stellate cells. Hepatology 74(4), 2170–2185 (2021).
- 24. Activation of BK channels prevents hepatic stellate cell activation and liver fibrosis through the suppression of TGFbeta1/SMAD3 and JAK/STAT3 profibrotic signaling pathways. Front. Pharmacol. 11, 165 (2020).
- 25. MicroRNA-98 inhibits hepatic stellate cell activation and attenuates liver fibrosis by regulating HLF expression. Front. Cell Dev. Biol. 8, 513 (2020).
- 26. . Exosomes derived from natural killer cells inhibit hepatic stellate cell activation and liver fibrosis. Hum. Cell 33(3), 582–589 (2020).
- 27. . miRNA-150-5p promotes hepatic stellate cell proliferation and sensitizes hepatocyte apoptosis during liver fibrosis. Epigenomics 12(1), 53–67 (2020).
- 28. Hepatic stellate cell activation promotes alcohol-induced steatohepatitis through Igfbp3 and SerpinA12. J. Hepatol. 73(1), 149–160 (2020).
- 29. . Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing. Theranostics 11(2), 614–648 (2021).
- 30. Inhibition mechanisms of CRISPR-Cas9 by AcrIIA17 and AcrIIA18. Nucleic Acids Res. 50(1), 512–521 (2022).
- 31. . New approaches to moderate CRISPR-Cas9 activity: addressing issues of cellular uptake and endosomal escape. Mol. Ther. 30(1), 32–46 (2022).
- 32. Correction: CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC. Leukemia 35(1), 294 (2021).
- 33. CRISPR/Cas9-mediated generation and analysis of N terminus polymorphic models of beta2AR in isogenic hPSC-derived cardiomyocytes. Mol. Ther. Methods Clin. Dev. 20, 39–53 (2021).
- 34. CRISPR-Cas9-mediated nuclear transport and genomic integration of nanostructured genes in human primary cells. Nucleic Acids Res. 50(3), 1256–1268 (2022).
- 35. Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications. J. Control. Release 343, 703–723 (2022).
- 36. Efficient in vivo liver-directed gene editing using CRISPR/Cas9. Mol. Ther. 26(5), 1241–1254 (2018).
- 37. . CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors. Cell 181(1), 136–150 (2020).
- 38. . Advances in peptide-mediated cytosolic delivery of proteins. Adv. Drug Deliv. Rev. 171, 187–198 (2021).
- 39. . Genome editing with mRNA encoding ZFN, TALEN, and Cas9. Mol. Ther. 27(4), 735–746 (2019).
- 40. . Delivery of CRISPR-Cas9 system for screening and editing RNA binding proteins in cancer. Adv. Drug Deliv. Rev. 180, 114042 (2022).
- 41. . Engineering exosomes for pulmonary delivery of peptides and drugs to inflammatory lung cells by inhalation. J. Control. Release 330, 684–695 (2021).
- 42. . Single extracellular vesicle analysis for early cancer detection. Trends Mol. Med. 28(8), 681–692 (2022).
- 43. . Extracellular vesicles for improved tumor accumulation and penetration. Adv. Drug Deliv. Rev. 188, 114450 (2022).
- 44. Hepatocyte-derived exosome may be as a biomarker of liver regeneration and prognostic valuation in patients with acute-on-chronic liver failure. Hepatol. Int. 15(4), 957–969 (2021).
- 45. Microfluidic-based exosome isolation and highly sensitive aptamer exosome membrane protein detection for lung cancer diagnosis. Biosens. Bioelectron. 214, 114487 (2022).
- 46. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. J. Hematol. Oncol. 15(1), 83 (2022).
- 47. . Engineering exosomes for targeted drug delivery. Theranostics 11(7), 3183–3195 (2021).
- 48. . Extracellular vesicle-based macromolecule delivery systems in cancer immunotherapy. J. Control. Release 348, 572–589 (2022).
- 49. Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model. J. Hepatol. 75(6), 1420–1433 (2021).
- 50. Oct4 and Hnf4alpha-induced hepatic stem cells ameliorate chronic liver injury in liver fibrosis model. PLOS ONE 14(8), e0221085 (2019).
- 51. FOXA2 alleviates CCl4-induced liver fibrosis by protecting hepatocytes in mice. Sci. Rep. 7(1), 15532 (2017).
- 52. . Delivery of an artificial transcription regulator DCAS9-VPR by extracellular vesicles for therapeutic gene activation. ACS Synth. Biol. 7(12), 2715–2725 (2018).
- 53. Exosome-mediated delivery of gene vectors for gene therapy. Nanoscale 13(3), 1387–1397 (2021).
- 54. Transcriptomics identify thrombospondin-2 as a biomarker for NASH and advanced liver fibrosis. Hepatology 74(5), 2452–2466 (2021).
- 55. The regulatory role and mechanism of autophagy in energy metabolism-related hepatic fibrosis. Pharmacol. Ther. 234, 108117 (2022).
- 56. Perturbation of specific signaling pathways is involved in initiation of mouse liver fibrosis. Hepatology 73(4), 1551–1569 (2021).
- 57. Generation of hepatic stellate cells from human pluripotent stem cells enables in vitro modeling of liver fibrosis. Cell Stem Cell 23(1), 101–113 e107 (2018).
- 58. . 3D in vitro models of liver fibrosis. Adv. Drug Deliv. Rev. 121, 133–146 (2017).
- 59. . Novel liver fibrosis model in Macaca fascicularis induced by thioacetamide. Sci. Rep. 10(1), 2450 (2020).
- 60. Pantoprazole ameliorates liver fibrosis and suppresses hepatic stellate cell activation in bile duct ligation rats by promoting YAP degradation. Acta. Pharmacol. Sin. 42(11), 1808–1820 (2021).
- 61. Glial cell line-derived neurotrophic factor (GDNF) mediates hepatic stellate cell activation via ALK5/Smad signalling. Gut 68(12), 2214–2227 (2019).
- 62. Correction to: a novel role of glutathione S-transferase A3 in inhibiting hepatic stellate cell activation and rat hepatic fibrosis. J. Transl. Med. 18(1), 182 (2020).
- 63. Silencing of EPCAM suppresses hepatic fibrosis and hepatic stellate cell proliferation in mice with alcoholic hepatitis via the PI3K/Akt/mTOR signaling pathway. Cell Cycle 18(18), 2239–2254 (2019).
- 64. miR-455-3p alleviates hepatic stellate cell activation and liver fibrosis by suppressing HSF1 expression. Mol. Ther. Nucleic Acids 16, 758–769 (2019).
- 65. Chronic liver injury induces conversion of biliary epithelial cells into hepatocytes. Cell Stem Cell 23(1), 114–122, e113 (2018).
- 66. Tumor necrosis factor-inducible gene 6 reprograms hepatic stellate cells into stem-like cells, which ameliorates liver damage in mouse. Biomaterials 219, 119375 (2019).
- 67. Brucella abortus infection elicited hepatic stellate cell-mediated fibrosis through inflammasome-dependent IL-1beta production. Front. Immunol. 10, 3036 (2019).
- 68. Hepatic stellate cell reprogramming via exosome-mediated CRISPR/DCAS9-VP64 delivery. Drug Deliv. 28(1), 10–18 (2021).
- 69. . Liver fibrosis: direct antifibrotic agents and targeted therapies. Matrix Biol. 68, 435–451 (2018).
- 70. . Gene therapy. Nature 564(7735), S5 (2018).
- 71. . Gene Therapy. N. Engl. J. Med. 381(5), 455–464 (2019).
- 72. Liver CPT1A gene therapy reduces diet-induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD. FASEB J. 34(9), 11816–11837 (2020).
- 73. Liver injury increases the incidence of HCC following AAV gene therapy in mice. Mol. Ther. 29(2), 680–690 (2021).
- 74. . Liver gene therapy and hepatocellular carcinoma: a complex web. Mol. Ther. 29(4), 1353–1354 (2021).
- 75. . The use of CRISPR/Cas9-based gene editing strategies to explore cancer gene function in mice. Curr. Opin. Genet. Dev. 66, 57–62 (2021).
- 76. In vitro and in vivo RNA Inhibition by CD9-HuR functionalized exosomes encapsulated with miRNA or CRISPR/DCAS9. Nano Lett 19(1), 19–28 (2019).
- 77. Fusion protein engineered exosomes for targeted degradation of specific RNAs in lysosomes: a proof-of-concept study. J. Extracell. Vesicles 9(1), 1816710 (2020).
- 78. Friend or foe? Evidence indicates endogenous exosomes can deliver functional gRNA and Cas9 protein. Small 15(38), e1902686 (2019).
- 79. An engineered exosome for delivering sgRNA: Cas9 ribonucleoprotein complex and genome editing in recipient cells. Biomater. Sci. 8(10), 2966–2976 (2020).
- 80. LECT2, a ligand for Tie1, plays a crucial role in liver fibrogenesis. Cell 178(6), 1478–1492, e1420 (2019).
- 81. MicroRNA-351 promotes schistosomiasis-induced hepatic fibrosis by targeting the vitamin D receptor. Proc. Natl. Acad. Sci. USA 115(1), 180–185 (2018).
- 82. . Activation of necroptosis by engineered self tumor-derived exosomes loaded with CRISPR/Cas9. Mol. Ther. Nucleic Acids 17, 448–451 (2019).
- 83. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517(7536), 583–588 (2015).